https://www.selleckchem.com/pr....oducts/Bortezomib.ht
In real-world clinical practice, biologics in inflammatory bowel diseases (IBD) may be discontinued for a variety of reasons, including discontinuation initiated by gastroenterologists. The aims of the study are to report outcomes after discontinuation and predictors of prognosis after a minimum follow-up of 24 months; outcomes of gastroenterologist-initiated discontinuation with resulting direct cost implications on the health system were also studied. IBD patients who discontinued their first-use biologics between January 2013 and
Like
Comment
Share
